Table 1.
Baseline characteristics of patients.
| Characteristics | Total(n = 146) n (%) | CDK-EVE(n = 56) n (%) | EVE-CDK(n = 90) n (%) | P value |
|---|---|---|---|---|
| Age, years, median (min, max) | 52.0(24.0, 79.0) | 52.0(31.0, 79.0) | 50.0(24.0, 74.0) | 0.386 |
| <65 years | 127(87.0 %) | 47(83.9 %) | 80(88.9 %) | |
| ≥65 years | 19(13.0 %) | 9(16.1 %) | 10(11.1 %) | |
| BMI, Kg/m2, median (min, max) | 23.2(15.6,38.8) | 0.580 | ||
| >25 | 24(16.4 %) | 8(14.3 %) | 16(17.8 %) | |
| ≤25 | 122(83.6 %) | 48(85.7 %) | 74(82.2 %) | |
| Menopausal status | 0.932 | |||
| Premenopausal or perimenopausal | 58(39.7 %) | 22(39.3 %) | 36(40.0 %) | |
| Postmenopausal | 88(60.3 %) | 34(60.7 %) | 54(60.0 %) | |
| Pathology | 0.267 | |||
| Invasive ductal carcinoma | 110(75.3 %) | 45(80.4 %) | 65(72.2 %) | |
| others | 36(24.7 %) | 11(19.6 %) | 25(27.8 %) | |
| Disease-free interval | 0.300 | |||
| Median, months(95%CI) | 57.8(50.4–65.2) | 53.0(41.1–64.9) | 59.9(52.7–67.1) | |
| Endocrine resistance status | 0.342 | |||
| Endocrine sensitivity | 59(40.4 %) | 24(42.9 %) | 35(38.9 %) | |
| Primary endocrine resistance | 20(13.7 %) | 10(17.9 %) | 10(11.1 %) | |
| Secondary endocrine resistance | 67(45.9 %) | 22(39.2 %) | 45(50.0 %) | |
| Metastatic sites at enrollment | ||||
| Lung | 75(51.4 %) | 28(50.0 %) | 47(52.2 %) | 0.794 |
| Liver | 81(55.5 %) | 37(66.1 %) | 44(48.9 %) | 0.042 |
| Bone | 94(64.4 %) | 38(67.9 %) | 56(62.2 %) | 0.489 |
| Brain | 10(6.8 %) | 4(7.1 %) | 6(6.7 %) | 1.000 |
| Bone-only metastasis | 13(8.9 %) | 2(3.6 %) | 11(12.2 %) | 0.132 |
| Non-visceral metastasis | 27(18.5 %) | 6(10.7 %) | 21(23.3 %) | 0.056 |
| Number of metastatic sites at enrollment | 0.510 | |||
| 1 | 32(22.0 %) | 12(21.4 %) | 20(22.2 %) | |
| 2 | 57(39.0 %) | 19(33.9 %) | 38(42.2 %) | |
| ≥3 | 57(39.0 %) | 25(44.7 %) | 32(35.6 %) | |
| Previous chemotherapy in metastatic setting at enrollment | 0.558 | |||
| 0 line | 63(43.2 %) | 27(48.2 %) | 36(40.0 %) | |
| 1 line | 40(27.4 %) | 12(21.4 %) | 28(31.2 %) | |
| 2 lines | 23(15.8 %) | 10(17.9 %) | 13(14.4 %) | |
| ≥3lines | 20(13.6 %) | 7(12.5 %) | 13(14.4 %) |
Abbreviations: CDK, Cyclin-dependent kinase 4/6 inhibitors; EVE, Everolimus; ER: Estrogen receptor; PR: Progesterone receptor; 1L: First-line treatment; 2L: Second-line treatment; 3L: Third-line treatment.